Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 2:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: l-carnitine Clear all
Completed Phase 2 Interventional

A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient

NCT00002184
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Levocarnitine, Adefovir dipivoxil, Saquinavir, Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
16 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 25, 2026, 2:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Clinical Trial to Evaluate the Effects of a Supplement on Symptoms Associated With Hormone Imbalance

NCT07765381
View directory record Official record
Conditions
Hormone Imbalance, Thyroid Hormone Imbalance, Low Energy, Metabolic Symptoms, Unhealthy Eating Habits
Interventions
Hello Burn, Balance Supplement
Dietary Supplement
Lead sponsor
Love Wellness
Industry
Eligibility
25 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 25, 2026, 2:12 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants

NCT01783041
View directory record Official record
Conditions
Prematurity, Neurodevelopmental Disorder, Carnitine Deficiency
Interventions
L-carnitine, 5% Dextrose
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
1 Day to 3 Days
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
2
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Sep 25, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Results available

Rapid Administration of Carnitine in sEpsis

NCT01665092
View directory record Official record
Conditions
Septic Shock
Interventions
Levo-Carnitine, placebo
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
14
States / cities
Birmingham, Alabama • Sacramento, California • Wilmington, Delaware + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Sep 25, 2026, 2:12 PM EDT
Completed Phase 2 Interventional

Developmental Study on Fatigue in Cancer

NCT00034450
View directory record Official record
Conditions
Neoplasms
Interventions
L-carnitine
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2006 · Synced Sep 25, 2026, 2:12 PM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

CARNIVAL Study: Gut Flora Dependent Metabolism of Dietary CARNItine and Phosphatidylcholine and cardioVAscuLar Disease

NCT01731236
View directory record Official record
Conditions
Dietary Modification
Interventions
Carnitine, Choline, Antibiotics, Choline and Aspirin, Carnitine and Aspirin
Dietary Supplement · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2029
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 25, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Results available

Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma

NCT00581919
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bort, Dex, and Dox with ALCAR
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
5
States / cities
Janesville, Wisconsin • La Crosse, Wisconsin • Madison, Wisconsin + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Sep 25, 2026, 2:12 PM EDT
Active, not recruiting Phase 3 Interventional

Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma

NCT05602194
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
Interventions
Biospecimen Collection, Calaspargase Pegol, Levocarnitine, Pegaspargase, Quality-of-Life Assessment
Procedure · Drug · Dietary Supplement + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
15 Years to 40 Years
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
225
States / cities
Birmingham, Alabama • Anchorage, Alaska • Kingman, Arizona + 149 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 25, 2026, 2:12 PM EDT
Withdrawn Phase 1 Interventional

Aberrations in Carnitine Homeostasis in Congenital Heart Disease With Increased Pulmonary Blood Flow

NCT01825369
View directory record Official record
Conditions
Heart Septal Defects, Ventricular, Atrioventricular Septal Defect
Interventions
IV L-carnitine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
2 Months to 12 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Sep 25, 2026, 2:12 PM EDT
Not listed Early Phase 1 Interventional

Use of Levocarnitine to Reduce Asparaginase Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia

NCT05501899
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Hepatotoxicity
Interventions
Levocarnitine
Drug
Lead sponsor
Children's Hospital of Orange County
Other
Eligibility
5 Years to 29 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Sep 25, 2026, 2:12 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Influence of OCTN2 Variants on Carnitine Status and Plasma Triglycerides

NCT00187733
View directory record Official record
Conditions
Carnitine Transporter Deficiency
Interventions
Fasting blood and urine collection
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 40 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2012 · Synced Sep 25, 2026, 2:12 PM EDT
Completed Phase 1 Interventional

Enhancing the Effects of Alcohol Treatment With L-Carnitine

NCT05355311
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
L-carnitine
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years to 25 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 14, 2025 · Synced Sep 25, 2026, 2:12 PM EDT
Enrolling by invitation Phase 2 Interventional

DMSO Dual-Route Therapy for Refractory Tinnitus in Long-COVID and Post-COVID-19 Vaccine Injury

NCT07567274
View directory record Official record
Conditions
Tinnitus
Interventions
DMSO-based otic solution with betahistine, dexamethasone, and lidocaine, DMSO-based transdermal cream with levocarnitine and N-acetylcysteine
Drug
Lead sponsor
Leading Edge Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Ithaca, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 25, 2026, 2:12 PM EDT
Terminated Phase 2 Interventional Results available

Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure

NCT02862600
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic, Cardiomyopathy, Hypertrophic, Familial
Interventions
Perhexiline, Use of bioanalytical assay to monitor plasma levels of perhexiline
Drug · Device
Lead sponsor
Heart Metabolics Limited
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
11
States / cities
Stanford, California • Indianapolis, Indiana • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Sep 25, 2026, 2:12 PM EDT
Completed Phase 2Phase 3 Interventional

L-carnitine for Fatigue in COPD

NCT03008356
View directory record Official record
Conditions
Copd, Fatigue
Interventions
L-carnitine 1000 mg twice daily, Weekly health coaching calls, Placebo capsules
Dietary Supplement · Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Sep 25, 2026, 2:12 PM EDT
Recruiting Phase 2 Interventional

Matching Perfusion and Metabolic Activity in HFpEF

NCT04913805
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Potassium Nitrate, Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside, Potassium Chloride
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 25, 2026, 2:12 PM EDT
Terminated No phase listed Observational

Long-Chain Fatty Acid Oxidation Disorders Online Disease Monitoring Program

NCT04812106
View directory record Official record
Conditions
Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
Interventions
No Intervention
Other
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Sep 25, 2026, 2:12 PM EDT
Withdrawn Phase 2 Interventional

Chronic Fatigue Syndrome: A Presumptive Mitochondrial Disorder

NCT01471652
View directory record Official record
Conditions
Chronic Fatigue Syndrome
Interventions
Nutraceutical supplements, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
25 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2015 · Synced Sep 25, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Results available

Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolled in Triheptanoin Studies

NCT02214160
View directory record Official record
Conditions
Carnitine Palmitoyltransferase (CPT I or CPT II) Deficiency, Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency, Long-chain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency, Trifunctional Protein (TFP) Deficiency, Carnitine-acylcarnitine Translocase (CACT) Deficiency
Interventions
UX007
Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
6 Months and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
9
States / cities
San Francisco, California • Washington D.C., District of Columbia • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Sep 25, 2026, 2:12 PM EDT
Not listed Not applicable Interventional

An Open-label Study of the Effects of Acetyl-L-Carnitine on Cardiovascular Outcomes in Friedreich's Ataxia

NCT01921868
View directory record Official record
Conditions
Friedreich's Ataxia
Interventions
Acetyl-L-Carnitine
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 11, 2016 · Synced Sep 25, 2026, 2:12 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Propionyl-L-Carnitine in the Treatment of Peripheral Arterial Disease (Intermittent Claudication)

NCT00399919
View directory record Official record
Conditions
Peripheral Vascular Diseases, Intermittent Claudication
Interventions
Propionyl-L-Carnitine, PLC
Drug
Lead sponsor
Sigma-Tau Research, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
9
States / cities
Jacksonville, Florida • Pensacola, Florida • LaGrange, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2011 · Synced Sep 25, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Results available

The Use of a Mitochondrial Enhancement Treatment in Bipolar Disorder

NCT00719706
View directory record Official record
Conditions
Bipolar Depression
Interventions
acetyl-l-carnitine PLUS alpha-lipoic acide, Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 17, 2012 · Synced Sep 25, 2026, 2:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy

NCT01537549
View directory record Official record
Conditions
Progressive Supranuclear Palsy
Interventions
alpha-lipoic acid and L-acetyl carnitine
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
40 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 25, 2026, 2:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study Of Nutraceutical Drinks For Cholesterol (Evaluating Effectiveness and Tolerability)

NCT01152073
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Placebo, Second Formulation, Third Formulation
Dietary Supplement
Lead sponsor
Healthy Drink Discoveries, Inc.
Other
Eligibility
20 Years to 80 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Sep 25, 2026, 2:12 PM EDT